TABLE OF CONTENTS

- Description p.1
- Impact Factor p.1
- Abstracting and Indexing p.1
- Editorial Board p.1
- Guide for Authors p.22

DESCRIPTION

*Translational Oncology* publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.

IMPACT FACTOR

2019: 3.558 © Clarivate Analytics Journal Citation Reports 2020

ABSTRACTING AND INDEXING

- PubMed/Medline
- Scopus
- Directory of Open Access Journals (DOAJ)

EDITORIAL BOARD

Co-Editors-in-Chief

**Bushra Ateeq**, Indian Institute of Technology Kanpur, Kanpur, India
Genetic/epigenetic alterations in prostate cancer, Cancer Biomarkers and Drug Targets, Mechanism of Drug resistance, non-coding RNAs in cancer.

**Justin Durla Lathia**, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, United States of America
Cancer stem cells, Glioblastoma, Cell-Cell Communication, Adhesion, Sex Differences

**Caroline E. Nunes-Xavier**, Radium Hospital Institute for Cancer Research, Oslo, Norway
Immune checkpoint proteins, Immunotherapy, Protein tyrosine phosphatase

**Günter Schneider**, Technical University of Munich Hospital Rechts der Isar, München, Germany
Analysis of signaling, cell cycle regulation, transcriptional regulation, and apoptosis, Molecular biology of GI-cancers

**Vivek Subbiah**, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, Houston, Texas, United States of America
Translational cancer research, early-phase biomarker-driven clinical trials, antibody drug conjugates, radio-pharmaceuticals, immunoconjugates and basket trials
Christian E. Badr, Harvard Medical School, Massachusetts General Hospital, Boston, United States of America
Brain tumors, Neurooncology

Adithya Balasubramanian, Baylor College of Medicine, Houston, Texas, United States of America
Therapeutic hypothermia, Stroke surgery, Animal behavior studies, Molecular biology, Cancer biology, SNP Genotyping, Sanger Sequencing, RNAseq

Pedro Barata, Tulane University, New Orleans, Louisiana, United States of America
Genitourinary tumors - prostate cancer, kidney cancer, bladder cancer, clinical trials, immunotherapy

Giusi Barra, National Research Council (CNR), ISMAC, Milano, Italy
Immunotherapy, immune system, cancer biology, drug discovery, cancer biomarkers, Tumor microenvironment

Pedro Barata, Tulane University, New Orleans, Louisiana, United States of America
Genitourinary tumors - prostate cancer, kidney cancer, bladder cancer, clinical trials, immunotherapy

Adithya Balasubramanian, Baylor College of Medicine, Houston, Texas, United States of America
Therapeutic hypothermia, Stroke surgery, Animal behavior studies, Molecular biology, Cancer biology, SNP Genotyping, Sanger Sequencing, RNAseq

Christian E. Badr, Harvard Medical School, Massachusetts General Hospital, Boston, United States of America
Brain tumors, Neurooncology

Giusi Barra, National Research Council (CNR), ISMAC, Milano, Italy
Immunotherapy, immune system, cancer biology, drug discovery, cancer biomarkers, Tumor microenvironment

Jared Barrott, Idaho State University, Pocatello, Idaho, United States of America
Sarcomas, Epigenetics, Precision Medicine

Define Bayik, Cleveland Clinic, Cleveland, Ohio, United States of America
Cancer immunotherapy, myeloid cells, immunosuppression TLR signalling

Elizabeth A. Beierle, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America

Edgar Ben-Josef, Ruth and Raymond Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States of America

Danielle Benedict L. Sacdalan, UP College of Medicine Department of Pharmacology And Toxicology, Manila, Philippines
Medical Oncology

Martin Benej, OHIO STATE UNIVERSITY, Columbus, Ohio, United States of America
Cancer metabolism, hypoxia, radiation oncology

Patrick R Benusiglio, Sorbonne University, Paris, France
Genetic susceptibility to cancer, in particular gastric, kidney and lung cancer, Lynch Syndrome, Genetic counseling in Oncology

Eijaz Bhat, Zhejiang University Life Science Institute, Hangzhou, China
Structural biology, Apoptosis, inflammation, membrane and cytosolic proteins, Cryo- electron microscopy, protein X-ray crystallography, TRAF signaling, Channel / Ion transporter

Elia Mario Biganzoli, University of Milan, Milan, Italy
DNA damage repair, Genomic Instability, Familial breast cancer, Homologous recombination, genotoxic chemotherapies

Jelena Bila, University of Belgrade, Belgrade, Serbia
Hematology, Multiple myeloma, Amyloidosis, Macroglobulinemia Waldenstrom

Andrew C Birkeland, University of California Davis, Davis, California, United States of America
Head and neck cancer

Giovanni Blandino, Regina Elena National Cancer Institute, Roma, Italy
Tumor Suppression, Non-Coding RNAs, Head and Neck Cancer, Metastasis

James A. Bonner, The University of Alabama at Birmingham O’Neal Comprehensive Cancer Center, Birmingham, Alabama, United States of America
Head and neck, metastatic disease

Corrine Bousquet, Cancer Research Center of Toulouse, Toulouse, France
Tumor Microenvironment

Jan Brábek, Charles University, Prague, Czechia
Cancer cell invasiveness and migration, integrin-mediated signaling

Dean Brenner, University of Michigan, Ann Arbor, Michigan, United States of America
General oncology and cancer prevention, Pharmacodynamics of anticancer drugs in animal models and humans

David N Brindley, Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, Alberta, Canada
Role of lipid mediators and inflammation in cancer progression and treatment by chemotherapy and radiotherapy with special interests in autotaxin, lysophosphatidic acid, lipid phosphate phosphatases

Kara Britt, Peter MacCallum Cancer Centre, Melbourne, Australia
Breast cancer cell biology, breast stem cells, hormonal regulation of cancer risk, microenvironment and cancer

James P. Brody, University of California Davis Biomedical Engineering Department, Sacramento, California, United States of America
Cancer genetic risk scores, cancer big data, computational science in cancer

James Brown, University of Limerick, Limerick, Ireland
Breast cancer, Biomarker identification, Genome stability

Adam M. Brufsky, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States of America
Breast cancer, immunology, clinical trials, molecular biology, endocrine therapy
Jan C Buckner, Mayo Clinic Rochester, Rochester, Minnesota, United States of America
Neuro-oncology, brain tumors
Robert Buono, University of California Irvine, Irvine, California, United States of America
Fasting, Cancer, Immunology
Emre Can Tüysüz, Lund University, Faculty of Medicine, Malmö, Sweden
Chordoma, miRNA, Cancer Stem Cell, Breast Cancer, Glioma, Role of Inflammation in Cancer Progression, Tumor Microenvironment
Huynh Cao, Loma Linda University, Loma Linda, California, United States of America
Hematologic malignancies (mainly acute myeloid leukemia)
Jian Cao, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States of America
Cancer epigenetics
Qi Cao, Northwestern University, Evanston, Illinois, United States of America
Epigenetics, miRNA, IncRNA, histone modifications, RNA modifications, prostate cancer, breast cancer, signal transduction
Giuseppe Cardillo
Lung cancer, lung cancer surgery, mesothelioma, thymoma, esophageal carcinoma, tracheal surgery, induction therapy in NSCLC
Karen-Sue Carlson, Versiti Blood Research Institute Milwaukee, Milwaukee, Wisconsin, United States of America
Hematopoiesis, leukemia, myelodysplastic syndrome, myeloproliferative disorders, fibrinolysis
Alessandro Carrer, Veneto Institute of Molecular Medicine, Padova, Italy
Pancreatic Cancer, Tumor metabolism, Cancer epigenetics
Litia Carvalho, University of New South Wales, Sydney, New South Wales, Australia
Immunogenetics, gastrointestinal cancer, microbiome
Ferdinando Cerelli, Inselspital University Hospital Berne Department of Medical Oncology, Bern, Switzerland
Mass spectrometry based proteomics, mesothelioma, thoracic cancer
Dafei Chai, Xuzhou Medical University, China
Renal cancer, Immune escape, Macrophage polarization, Tumor immunotherapy
Peiwei Chai, Shanghai Jiao Tong University, Shanghai, China
Ocular malignancies (retinoblastoma, uveal melanoma), long non-coding RNAs (IncRNAs), genetic testings, RNA modifications (m6A, m5C, m1A)
Sakti Chakrabarti, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America
Medical oncology, GI oncology, Colorectal cancer, Gastric cancer, Esophageal cancer, circulating tumor DNA, Immunotherapy
Abhishek Chakraborty, Cleveland Clinic, Cleveland, Ohio, United States of America
Hypoxia, Cancer Stem-like Cells, Epigenetics, Kidney Cancer, Dioxygenases
Sayan Chakraborty, Institute of Molecular and Cell Biology, Singapore, Singapore
Tumor microenvironment, tumor angiogenesis, liver cancer, Hippo pathway, the extracellular matrix in cancer, mechanotransduction in cancer, cancer reprogramming, cancer cell signaling, targeted therapies
Parthasarathy Chandrakesan, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America
Immunoncology, Cell of origin of cancer, Tumor stem cells, Drug resistance, Tumor microenvironment, Targeted therapy, and immunotherapy
Pratik Chandran, Advanced Centre for Treatment Research and Education in Cancer, Navi Mumbai, India
Sampurna Chatterjee, Harvard Medical School, Boston, Massachusetts, United States of America
Immunoncology, Pediatric and adult brain cancers, Lung cancer, Tumor microenvironment, molecular signaling, targeted therapy
Ioulia Chatzistamou, University of South Carolina, Columbia, South Carolina, United States of America
Breast cancer pathology, cytokines and metastasis, animal models of cancer, colon cancer and metabolism
Alcides Chaux, University of the North, Asuncion, Paraguay
Genitourinary pathology, data science, statistics, cancer biology, molecular biology, immunohistochemistry, prognosis, prognostic models, machine learning
Guoliang Chen, Jiangsu Hengrui Medicine Co Ltd, Lianyungang, China
Clinical trial, Meta analysis, Cancer, IncRNA, circRNA
Hui-Zi Chen, OHIO STATE UNIVERSITY, Columbus, Ohio, United States of America
Genomics, molecular biology, cell biology, small cell lung cancer, GI cancers
Jason Chen, Saint John's University College of Pharmacy and Allied Health Professions, New York, New York, United States of America
Cancer Pharmacology

Liubo Chen, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, China
Management and prevention of gastrointestinal cancer, Molecular mechanisms of colorectal cancer

Sidi Chen, Yale University, New Haven, Connecticut, United States of America
Genetics, genomics, immunology, gene editing, CRISPR, cancer, cancer immunology, CAR-T, cell therapy, gene therapy

Siqi Chen, Beckman Research Institute, Duarte, California, United States of America
Immuo-Oncology, Tumor Microenvironment, Therapeutic Antibody Discovery, Cellular Therapy, Therapeutic Recombinant Fusionprotein Discovery

Samuel Cheshier, University of Utah Health Hospitals and Clinics, Salt Lake City, Utah, United States of America
Pediatric Neurosurgery

James C. S Chim, University of Hong Kong, Hong Kong, China
Myeloma, Lymphoma, Epigenetics, DNA Methylation

Minsig Choi, Stony Brook University Cancer Center, Stony Brook, New York, United States of America
Gastrointestinal Cancers And Translational Oncology Research

Kin-Hoe Chow, Boston Children's Hospital, Boston, Massachusetts, United States of America
Oncology, Breast cancer, Pancreatic cancer, Cancer Biomarkers, Metalloproteases, Tumor angiogenesis, Tumor microenvironment, Obesity-associated cancer, Tumor dormancy

Chris Kong Chu Wong, Hong Kong Baptist University, Kowloon, Hong Kong
Molecular Endocrinology and Toxicology

Hsiang-Hao Chuang, Kaohsiung Medical University, Kaohsiung, Taiwan
Cell signaling, protein turnover, centrosome, genome stability

Anatolii Chumak, SI National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
Chronic lymphocytic leukemia/gene of Lypoproteinlipase expression

Looi Chung Yeng, Taylor's University, Subang Jaya, Malaysia
Natural product, drug screening, molecular biology, cancer development

Bekir Cinar, Clark Atlanta University Center for Cancer Research and Therapeutic Development, Atlanta, Georgia, United States of America
Signal Transduction, gene Expression, genomics, Proteomics, Bioinformatics, 3DCell Cultures

Giovanni Codacci-Pisanelli, Sapienza University of Rome, Rome, Italy
Fertility in oncology (Oncofertility), medical oncology, pharmacology

Jordi Codony-Servat, Dexeus University Hospital, Barcelona, Spain
Signaling transduction and drugs against cancer

Norman Coleman, National Cancer Institute, Bethesda, Maryland, United States of America
Radiation oncology, radiation biology, molecular targeted therapy, radiation stress response for tumor and normal tissue, global health, health disparities

Fabio Conforti, European Institute of Oncology, Milan, Italy
Breast Cancer, Lung Cancer, Rare Tumors, biomarkers and molecular mechanisms of resistance of targeted therapies

Kevin Conlon, National Cancer Institute, Bethesda, Maryland, United States of America
Immunotherapy, cytokine therapy

Joseph N. Contessa, Yale Cancer Center, New Haven, Connecticut, United States of America
Neoplastams, Radiobiology, Chemicals and Drugs

Maria Cristina Rapanotti, University of Rome Tor Vergata, Roma, Italy
Minimal residual disease, the analysis of angiogenic markers and in the cascade involving cell adhesion molecules and consequently matrix-metallo-proteases, particularly in melanoma and in onco-haematology, Liquid biopsy, behavior of the CD146 / MCAM / MUC18n surface antigen in oncology, as a marker of disease progression in malignant melanoma

Pierfilippo Crucitti, Campus Bio-Medico University Hospital, Roma, Italy
Lung Cancer, Immunotherapy
cancer biology, oral pathology, biomarkers and molecular mechanisms of tumor progression

**Juanjuan Dai**, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Pancreatic cancer, pancreatitis, tumor microenvironment, microRNA, gut microbiota

**Bhudev C. Das**, Amity University Amity Institute Of Molecular Medicine & Stem Cell Research, Noida, India
Molecular & Clinical Oncology, HPV (Cervical Cancer, Breast Cancer and Head & Neck Cancer), Transcriptional Regulation, miRNA biology, Stem Cells, Cancer Stem Cell, Chemoprevention

**Yi Y. David Xu**, LOMA LINDA UNIVERSITY MEDICAL CENTER, Loma Linda, California, United States of America
Leukemia Research

**Alessandra De Leo**, Moffitt Cancer Center, Tampa, Florida, United States of America
Tumor virology, EBV, KSHV, Epigenetics

**Theodore DeWeese**, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
Bioinformatics, biomedical informatics, cancer, genomics, systems biology

**Zhongbin Deng**, University of Louisville, Louisville, Kentucky, United States of America
Tumor immunology in colon cancer and liver cancer, Mucosal immunology, Host-microbiota interaction at mucosal surface, and Pathogenesis of inflammatory bowel diseases

**Arikketh Devi**, SRM Institute of Science and Technology, Kattankulathur, India
Cancer Biology, Stem Cell Biology

**Bharti Devnani**, All India Institute of Medical Sciences, New Delhi, India
Oncology, Radiation Oncology, SBRT, Breast cancer, Head and neck cancers, CNS tumors, Cancer

**Nihat Dilsiz**, Istanbul Medeniyet University, Istanbul, Turkey
Molecular Biology, Cell Biology, Biotechnology, Genetics, Biochemistry, Cancer Research, Neuroscience, Methods

**Konstantinos Dimas**, University of Thessaly Faculty of Medicine, Larisa, Greece
Drug discovery and development, drug delivery systems, animal models of cancer (syngeneic, xenografts, GEMM), signaling, small molecules

**Umut Disel**, Acibadem Hospitals Group Department of Medical Oncology, Adana, Turkey
Clinical oncology, Precision medicine trials, Genome sequencing (exome-Whole), Immunooncology and exceptional responders-case studies and Molecularly targeted therapies.

**Nabil Djouder**, Spanish National Cancer Research Centre, Madrid, Spain
Liver and intestinal diseases, cancer, metabolism, endocrino-physiology

**Kenneth Dornfeld**, University of Minnesota, Minneapolis, Minnesota, United States of America
Radiation oncology, radiosurgery

**Eloïse Dray**, The University of Texas Health Science Center at San Antonio School of Dentistry, San Antonio, Texas, United States of America
DNA damage repair, Genomic Instability, Familial breast cancer, Homologous recombination, genotoxic chemotherapies

**Raymond Dubois**, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, Houston, Texas, United States of America
Cancer prevention, tumor microenvironment, inflammation and cancer, colorectal cancer biology, early disease progression, Intestinal epithelial biology, cancer stem cell biology, cancer interception

**Audrius Dulskas**, Vilnius University Faculty of Medicine, Vilnius, Lithuania
Colorectal cancer, minimal invasive techniques, quality of life, functional changes

**Pankaj Dwivedi**, Genentech Inc, South San Francisco, California, United States of America
Proteomics, Data Science

**Avraham Eisbruch**, University of Michigan Department of Radiation Oncology, Ann Arbor, Michigan, United States of America
Head and neck cancer, IMRT, QOL

**Eman Ahmed Elghoroury**, National Research Centre, Cairo, Egypt
Molecular biology, mRNA, Gene polymorphism, Flow cytometr analysis, PCR, qPCR, clinical pathology, haematology and immunology

**Deilson Elgui de Oliveira**, Sao Paulo State University Julio de Mesquita Filho - Botucatu Campus, Botucatu, Brazil
Viral carcinogenesis, Tumor virology, Epstein-Barr Virus, Kaposi Sarcoma Herpesvirus, Epithelial-Mesenchymal Transitions (EMT), Cancer Stem Cells (CSC), Tumor progression, Cancer metastasis
Moshe Elkabets, Ben-Gurion University of the Negev, Be'er Sheva, Israel  
Cancer therapy, immunotherapy, head and neck cancer biology, signalling PI3K and MAPK pathways

Anwar Abd Elnaser, The American University in Cairo, New Cairo, Egypt  
Oncology, gastroenterology, and immunotherapy

Mariana Emerenciano, National Institute for Cancer, Rio de Janeiro, Rio de Janeiro, Brazil  
Translational cancer research, molecular biology, hematological malignancies, acute leukemias, human genetics

Ahmet Emre Eşkazan, Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine, Fatih, Turkey  
Acute leukemias, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myeloproliferative neoplasms

Emily Esakov, Cleveland Clinic Foundation, Cleveland, Ohio, United States of America  
Oncology, metabolism, gene therapy, melanoma

Laura Evangelista, Veneto Institute of Oncology Institute for Hospitalization and Care Scientific, Padua, Italy  
Developmental therapeutic, targeted therapy combinations in genetically defined subsets of solid tumor cancers, pediatric cancers

Ruitai Fan, Zhengzhou University First Affiliated Hospital, Zhengzhou, China  
Radiotherapy and chemotherapy for esophageal cancer

Eric Fearon, University of Michigan, Ann Arbor, Michigan, United States of America  
Knowledge synthesis reviews (systematic reviews, scoping reviews, rapid reviews)

Francisco Winter dos Santos Figueiredo, Medical Faculty of the ABC, SANTO ANDRE, Brazil  
Cancer epidemiology, cancer, social epidemiology, social determinants, public health

Sinem Firtina, Istinye University Department of Molecular Biology and Genetics, Istanbul, Turkey  
Leukemia, B-ALL, T-ALL, Next Generation Sequencing

William Flavahan, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America  
Epigenetics, Chromatin Biology and Topology, Cancer Stem Cells, Glioma

Gianluca Franceschini, University Hospital Agostino Gemelli, Rome, Italy  
Breast Cancer, Surgical Treatment, Oncoplastic Techniques

Giorgio Frega, University of Bologna Department of Specialized Diagnostics and Experimental Medicine, Bologna, Italy  
Clinical trials, Murine models, Next Generation Sequencing, Cell culture, Immunofluorescence, Western blotting

Hermann B. Frieboes, University of Louisville, Louisville, Kentucky, United States of America  
Mathematical modeling, computational simulation, machine learning, nanotherapy, immunotherapy, metabolomics

Daniel E. Frigo, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, Houston, Texas, United States of America  
Areas of Expertise: Prostate cancer; Nuclear receptors; Androgens; Molecular endocrinology; Metabolism

Steven Gameiro, McMaster University, Hamilton, Ontario, Canada  
Tumor virology, Tumor Immunology, Cancer Immunotherapy

Vadim Gaponenko, University of Illinois at Chicago Cancer Center, Chicago, Illinois, United States of America  
Signaling Pathways, Molecular Biology, Drug Discovery, Biochemistry, Cancer Biology

Emmanuel Garcion, INSERM, Research Unit 999, Le Plessis Robinson, France  
Cancer and Immunology Research, nanomedicine

Thomas Gardner, Indiana University Bloomington, Bloomington, Indiana, United States of America  
Urologic Oncology, clinical trials, medical devices, molecular imaging

David Garrick, University of Paris Saint Louis Research Institute, Paris, France  
Epigenetics, long non-coding RNA, multiple myeloma, hematopoietic stem cells, gene regulation

Patrizia Gasparini, Foundation IRCCS National Cancer Institute, Milan, Italy  
Molecular Biology, Cell Biology, Cancer

Mehran Ghasemzadeh, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran  
Thrombosis, Platelets, Transfusion, HSCT, NK cell, Innate immunology, HLA-E
Michele Ghidini, IRCCS Maggiore Hospital, Ospedale Maggiore Policlinico, Milan, Italy
Gastrointestinal cancers, gastric cancer, liver cancer, colorectal cancer, pancreatic cancer, esophageal cancer

Mithua Ghosh, HealthCare Global Enterprises Ltd, Bangalore, India
Molecular and Clinical Genomics

Fernando Gianfrancesco, National Research Council of Italy, Naples, Italy
Bone tumors, skeletal diseases, diseases predisposing to bone tumors

Alessio Giuseppe Morganti, University of Bologna, Bologna, Italy
Gastrointestinal tumors, prostate tumors, new technologies in radiation oncology (Stereotactic, Intensity Modulated Radiotherapy, VMAT), palliative radiotherapy,

Shom Goel, Peter MacCallum Cancer Centre, Melbourne, Australia
Breast Cancer, Cell Cycle Biology, Cancer Epigenetics

Yesim Gökmen-Polar, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
Breast Cancer, Cancer Biology, Therapeutic Targets, Experimental Therapeutics, Mechanisms of Drug Resistance

Ana Cristina Gonçalves, University of Coimbra Faculty of Medicine, Coimbra, Portugal
Oncobiology, Epigenetics, Genetics, DNA damage repair, Oxidative stress, Biomarker, Targeted therapy, Drug resistance

Denise Gonçalves Prioli, University of California San Francisco School of Medicine,, United States of America
Colorectal Cancer, Biomarkers in Colorectal Cancer, Animal MOdels in Cancer, Immunohistochemistry

Kylie L Gorringe, Peter MacCallum Cancer Centre, Melbourne, Australia
Cancer genomics, Ovarian cancer, Breast cancer, Biomarkers, Organoids

Humaira Gowher, Purdue University Department of Biochemistry, West Lafayette, Indiana, United States of America
Epigenetics

Magdalena M. Grabowska, Case Western Reserve University, Cleveland, Ohio, United States of America
Prostate cancer (androgen receptor, transcription factors, mechanisms of therapeutic resistance), bladder cancer

Giovanni Grandi, University Hospital Modena, Modena, Italy
Ovarian cancer, Hereditary ovarian cancer, BRCA, endometrial cancer prevention, Hereditary uterine cancer, mismatch-repair, cervical cancer

Alexandru Calin Grigorescu, Hospital of Nephrology Dr Carol Davila, Bucureşti, Romania
Medical Oncology, Palliative care

Sebastian Grosicki, Medical University of Silesia, Faculty of Health Sciences in Bytom, Department of Hematology and Cancer Prevention in Chorzow, Katowice, Poland
Hematology, internal medicine, therapy and diagnostics of multiple myeloma, acute leukemias, chronic leukemias

Barbara T. Grünwald, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada
Tumor Microenvironment, Pancreatic Cancer, Metastasis, Functional Genetic Models

Sukru Gulluoglu, Marmara University, Istanbul, Turkey
Cancer, non-coding RNA, Tumor Promoting Inflammation, Cell Biology

Manoj Gupta, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
Nuclear Oncology

Ritu Gupta, All India Institute of Medical Sciences, New Delhi, India
Diagnostic Hemato-Oncology, Multiple myeloma, Flow cytometry, Acute leukemia, Image processing, CLL

Ken H. Young, Duke University Medical Center, Durham, North Carolina, United States of America
Diagnosis of hematologic cancers, lymphoma and myeloma pathology, molecular and genetic biomarkers for classification of blood cancer and lymphoid neoplasms, all types of leukemia, myeloid neoplasm, lymphoma, myeloma and benign hematologic disorders, acute and chronic leukemia, myelodysplastic syndromes, myeloproliferative disorders, anemias and cytopenia, benign bone marrow and lymph node disorders, B-cell lymphomas and T-cell lymphomas and cutaneous lymphomas, molecular diagnostics, flow cytometry, cytogenetic and FISH analysis and specialized bone marrow testing

Franziska Haderk, University of California San Francisco, San Francisco, California, United States of America
Exosomes, drug resistance to target kinase inhibitors, and tumor microenvironment

Hanne R. Hagland, University of Stavanger, Stavanger, Norway
Mitochondrial physiology, cancer cell metabolism, glycolytic contributions in cancer, colorectal cancer, pancreatic cancer, cancer spheroids

Feda H. Hamdan, Mayo Clinic Rochester, Rochester, Minnesota, United States of America
Pancreatic cancer, gene transcription regulation, epigenetics and Integrative Bioinformatics

Mu Hao, Chinese Academy of Medical Sciences Institute of Hematology and Blood Diseases Hospital, Tianjin, China
The pathogenesis of Plasma cell malignancise, especially focus on the Multiple Myeloma and Waldenström's Macroglobulinema

**Daniel Hayes**, University of Michigan, Ann Arbor, Michigan, United States of America
Breast cancer

**Stephanie Herkenne**, University of Liege, Liege, Belgium
Angiogenesis, Cancer, mitochondria dynamics, miRNA, signaling pathways

**Daniel Herranz**, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States of America
Leukemia, Mouse Models of Cancer, Long-Range Transcriptional Regulation, Cancer Metabolism

**Elisabeth Hessmann**, University Medical Center Goettingen, Department of Gastroenterology and gastrointestinal Oncology, Göttingen, Germany
Pancreatic cancer, transcription, chromatin regulation

**Anita Hjelmeland**, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America
Cancer cell biology, Neuro-oncology

**Markus Hoffmann**, Kiel University, Kiel, Germany
Human Papillomavirus infection in head and neck cancer, sexual behavior and HPV infection, comorbidity in head and neck cancer therapy, SLPI and Annexin A2 in HPV associated and not associated cancers

**Hubert Hondermarck**, The University of Newcastle, Newcastle, New South Wales, Australia
Breast cancer, Cancer Biology, Growth factors, Prostate cancer, Receptor Tyrosine Kinases, Signal Transduction, Signaling Molecules, Tyrosine Kinases, signal transduction, signal transduction, signal transduction, breast cancer, breast cancer, breast cancer, proteomics, proteomics, proteomics, growth factor, growth factor, growth factor.

**Craig Horbinski**, Northwestern University, Evanston, Illinois, United States of America
Neuropathology, brain tumors

**Lucas A. Horn**, National Cancer Institute, Bethesda, Maryland, United States of America
Tumor immunology/immunotherapy, tumor microenvironment, epithelial-mesenchymal transition, MDSC

**Mustafa Ozan Horsanali**, Bakircay University Cigli Training and Research Hospital, İzmir, Turkey
Oncology, Endourology, Neuro-urology

**Rashmi Maruti Hosalkar**, MGM Dental College and Hospital, Mumbai, India
Oral Oncology, Oral Potentially Malignant Disorders, Odontogenic Cyst and Tumours, Vesiculobullous Lesions

**Peng Hou**, Xi'an Jiaotong University Medical College First Affiliated Hospital, Xian, China
Cancer Biology; Targeted therapy; Epigenetics

**Stanley Huang**, Case Western Reserve University Department of Pathology, Cleveland, Ohio, United States of America
Brain tumors, Glioblastoma, Cancer stem cells, 3D culture, organoids

**Laura Hulea**, University of Montreal, Montreal, Quebec, Canada
Molecular and cellular biology, cancer, mRNA translation and cellular metabolism

**Wen-Chun Hung**, National Institute of Cancer Research, Zhunan, Taiwan
Cancer Biology, Pancreatic cancer, Genetically modified animal models, Breast cancer, Signal transduction

**Fahmeed Hyder**, Yale University, New Haven, Connecticut, United States of America
Magnetic resonance, metabolic imaging, neuroimaging, cancer imaging, tumor microenvironment

**Ignacio varela**, University of Cantabria, Santander, Spain
Cancer Genomics, Next-generation sequencing, chromatin remodelling

**Vamvakaris N. Ioannis**, Sotiria General Hospital of Chest Diseases of Athens, Athens, Greece
NSCLC, MSC in oncology

**Juan L Iovanna**, Cancer Research Centre Marseille, Marseille, France
Pancreatic cancer (genetics, transcriptomics, proteomics, personal treatments, molecular and cellular biology), preclinical studies

**Khushboo Irshad**, All India Institute of Medical Sciences, New Delhi, India
Cancer genetics, Glioma biology, Cell signaling, Tumor microenvironment, Inflammation

**Panagiotis J. Vlachostergios**, Weill Cornell Medicine, New York, New York, United States of America
Genitourinary cancers (prostate, urothelial, kidney), genetics, cancer genomics, genomic cancer risk assessment, cancer immunotherapy

**Sankar Jagadeeshan**, Ben-Gurion University of the Negev, Be'er Sheva, Israel
Drug resistance mechanism, molecular oncology, cell signaling, translational medicine, cancer chemoprevention, in vitro and in vivo models, immunotherapy

**Murali Janakiram**, University of Minnesota, Minneapolis, Minnesota, United States of America
Lymphoma, Myeloma, Cellular therapy
Jin Sung Jang, Mayo Clinic Department of Laboratory Medicine and Pathology, Rochester, Minnesota, United States of America
Cancer genetics, Genomics, Transcriptome, Single cell biology, Lung cancer, Never smoker
Pradeep Jangampalli, Texas Tech University, Lubbock, Texas, United States of America
Cancer Genomics, Bioinformatics, Drug Discovery, toxicology, Pharmacology, protein modeling, virtual screening, computational biology, Cancer Therapeutics
Bertrand Jean-Claude, Research Institute of the McGill University Health Centre, Montréal, Quebec, Canada
Drug discovery/Therapeutics
Mingjie Jiang, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Pancreatic cancer, radiotherapy, tumor microenvironment, tumor recurrence, non-coding RNA
Mohit Kumar Jolly, Indian Institute of Science, Bengaluru, India
Metastasis, Systems Biology, Phenotypic plasticity, Epithelial-mesenchymal transition, Cancer Stem cells
Dianwen Ju, Fudan University School of Pharmacy, Shanghai, China
Cancer Immunotherapy, Immunology
Jin Juan, Fudan University Shanghai Cancer Center, Shanghai, China
Breast Cancer, Immunotherapy, DNA Damage Response
Vladimir Jurisic, University of Kragujevac Faculty of Medical Sciences, Kragujevac, Serbia
Immu-no-oncology, Basic science, Hematology, Molecular oncology, immunology
Asta Juzeniene, Luxembourg Institute of Health, Strassen, Luxembourg
Chronic Lymphocytic Leukemia CLL, tumor microenvironment, exosomes, extracellular vesicles, anti-tumor immunity, hematological malignancies
Sarada Preeta Kalainayakan, University of Texas at Dallas, Richardson, Texas, United States of America
Molecular biology, Cell biology, Cancer biology, Metabolism, Lung cancer
Murugan Kalimutho, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
Breast and colorectal cancer, cell cycle, cell signaling, DNA damage repair, targeted therapy, resistance
Mohamed Gomaa Kamel, Minia University Faculty of Medicine, El Minia, Egypt
Biomarkers, Diagnosis, Prognosis, Immunology, Clinical Research, Epidemiology, Prevention, Public Health, Biostatistics, Prediction, Diagnostic Accuracy, Regression, Survival Analysis, Systematic Review, Meta-analysis
Govind Babu Kanakasetty, St John's Medical College Hospital, Bangalore, India
Medical oncology, NSCLC and HNSCC
Salma Kaochar, Baylor College of Medicine, Houston, Texas, United States of America
Prostate cancer, racial disparities in prostate cancer
Gökşürgen Karabiyik, Koc University, Istanbul, Turkey
Epigenetics, Cancer Biology (specifically Medulloblastoma), CRISPR/Cas9, Drug Resistance, Targeted Delivery
Abdullah Karadağ, TUBİTAK Marmara Research Centre, Gebze, Turkey
Tumor bone disease, Mechanism involved in metastatic cascade, Biomarkers in cancer, Integrative multiomics (genomics, transcriptomics, proteomics, metabolomics, etc.), SIBLING, MMP, ADAM, Integrin protein families, CAR-T cell therapy
Mythreye Karthikeyan, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America
Ovarian cancer, TGF, BMP, Activin/Inhibin, EMT, Cell survival mechanisms
Manuel Kaulich, Goethe University Frankfurt, Frankfurt am Main, Germany
Gene editing, genetic screening, cell and cancer biology
Bhumsuk Keam, Seoul National University College of Medicine Department of Internal Medicine, Seoul, South Korea
Head and neck cancer, lung cancer, immuno-oncology, clinical trial
Wan Hang Keith Chiu, The University of Hong Kong, Pokfulam Road, Hong Kong
Gastrointestinal imaging, Oncological imaging, PET, Artificial Intelligence and Machine Learning
Krishnendu Khan, Cleveland Clinic, Cleveland, Ohio, United States of America
Cancer Biology, translation regulation
Francesca Khani, Weill Cornell Medicine, New York, New York, United States of America
Urologic pathology, breast pathology
Dhanachandra Khuraijam, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, United States of America
Structural Bioinformatics, Drug Discovery, GPCRs
Thomas Kietzmann, University of Oulu Faculty of Biochemistry and Molecular Medicine, OULU, Finland
Hypoxia, Hypoxia-inducible factors, Redox biology, reactive oxygen species, Liver, Hepatocytes, Cancer metabolism, Antioxidants, Kinase signalling, proteasome, proteasome inhibitors, ubiquitin ligases, protein degradation
Thomas Karsten Kilvaer, UiT The Arctic University of Norway, Tromsø, Norway
Cancer biology, cancer biomarkers, artificial intelligence, sarcoma, NSCLC, radiotherapy

Hong Sook Kim, Sungkyunkwan University, Jongno-gu, South Korea
Cancer genomics, epigenetics, gene regulation, cancer immunotherapy

Jongphil Kim, H. Lee Moffitt Cancer Center and Research Institute Department of Biostatistics and Bioinformatics, Tampa, Florida, United States of America
Biostatistics, Design and Analysis of Phase I/II Clinical Trials, Multiple Comparisons, Time-To-Event Data Analysis, Concordance Analysis, BMT, Malignant Hematology, Imaging Data Analysis, Thoracic Oncology

Maximilian Kordes, Karolinska Institute, Huddinge, Sweden
Pancreatic cancer, gastric and GEJ cancer, biliary tract cancers, circulating nucleic acids, extracellular vesicles, early clinical trials

Hanna Kosela-Paterczyk, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Warszawa, Poland
Chemotherapy, Immunotherapy, Melanoma, Oncology Clinical Research

Oliver H. Krämer, University Medical Center, Department of Pharmacology Toxicology, Mainz, Germany
HDAC, HDAC inhibitors, PR130, FLT3, JAK2

Donald Kufe, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
Cancer medicine

Rohit Kumar, University of Louisville, Louisville, Kentucky, United States of America
Thoracic malignancy, Head and neck cancer, thrombosis

Vinod Kumar, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
Cancer biology, microRNA, Nanomedicine, Tumor microenvironment, Cell signaling, Drug discovery and Drug delivery, Structural Biology of Proteins, RNA Sequencing, Proteomics

Elena Kuzmin, McGill University Rosalind and Morris Goodman Cancer Research Centre, Montréal, Quebec, Canada
Cancer Genomics, Cancer Genetics, Functional Genomics, Yeast Genetics, Genetic Networks

Kwong Kwok Wong, The University of Texas MD Anderson Cancer Center Division of Surgery, Houston, Texas, United States of America
Ovarian Cancer, Genomics, uterine cancer, pediatric brain tumor

Roberto La Rocca, University of Naples Federico II Department of Neuroscience and Reproductive Sciences and Dentistry, Napoli, Italy
Urology, prostate cancer, kidney cancer, bladder cancer, penile cancer, urethral strictures.

Ezio Laconi, University of Cagliari, Cagliari, Italy
Cancer biology, liver patophysiology, regenerative medicine, aging

El-Nasir Lalani, The Aga Khan University, Karachi, Pakistan
Stem cell and cancer biology, pathology, bio-banking, and bioethics

Eric Lam, Imperial College London, London, United Kingdom
Transcription; Chromatin; Signalling Cancer, DNA damage response, Drug resistance.

Matteo Lambertini, University of Genoa, Genova, Italy
Breast cancer and survivorship, more specifically, breast cancer in young women, BRCA, fertility and pregnancy-related issues

Denis Ulises Landaverde, Costa Rica University, San José, Costa Rica
Breast Cancer, Medical Oncology

Frederick F. Lang, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, Houston, Texas, United States of America
Neurosurgery

Sara Laudato, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, Houston, Texas, United States of America
Cancer Biology, Cell Biology, Molecular Genetics, Therapy Resistance

Charalampos Lazaris, Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, United States of America
Nuclear Organization, Transcriptional Regulation, Cancer Epigenetics, Hematological malignancies, Pediatric Cancer

Dung-Fang Lee, University of Texas Health Science Center at Houston, Houston, Texas, United States of America
iPSC disease model, osteosarcoma

Lorenzo Leoncini, University of Siena, Siena, Italy
Haematopathology

Monika Lewinska, University of Copenhagen, Copenhagen, Denmark
Metabolomics, 'omics' integration, liver cancer, metabolic stress, metabolic associated fatty liver disease, tumor microenvironment

Chunrui Li, Tongji Hospital Affiliated to Tongji University, Shanghai, China
Car-T Cell Therapy, MM AND Lymphoma

Zhi-Cheng Li, Shenzhen Institutes of Advanced Technology Chinese Academy of Sciences, Shenzhen, China
Medical image analysis/visualizations/displays, machine learning, radiomics/radiogenomics

Tiao Lin, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China
Osteoporosis, peri-prosthetic infection/bone loss, osteosarcoma, radiotherapy, chemotherapy

Clifton Ling, Memorial Sloan Kettering Cancer Center, New York, United States of America
Liver transplantation and Hepato-bilio-pancreatic oncology

Qi Ling, Zhejiang University School of Medicine, Hangzhou, China
Urologic oncology, prostate cancer, tumor microenvironment, mouse models of cancer, extracellular vesicles, robotic surgery

Mikhail Lisovsky, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, United States of America
Gastrointestinal pathology

Gang Liu, Xiamen University, Xiamen, China
Drug delivery, Molecular imaging, Biomaterials

Junqi Liu, The First Affiliated Hospital of Zhengzhou University, Department of Radiology, Zhengzhou, China
Radiosensitization of tumors, Radioprotection of normal tissues

Yang Liu, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland, United States of America
Neuro-oncology, Molecular biology, Cellular biology, DNA damage, Redox homeostasis, Translational medicine, Glioma, Chemotherapy, IDH mutation, Cancer metabolism

Luca Giovanni Locatello, University Hospital Careggi, Firenze, Italy
head and neck cancer, laryngeal cancer, salivary gland cancer, oral cavity cancer, otolaryngology-head and neck surgery, otorhinolaryngology

Kristopher A. Lofgren, Gunderson Medical Foundation, La Crosse, Wisconsin, United States of America
Breast Cancer, Cell Signaling (growth factors, kinases, nuclear receptors), Mouse Models of Cancer, Mammary Gland Development

Ines Lohse, University of Miami, Miami, Florida, United States of America
Drug development, Drug screening, pancreatic cancer, sarcoma, AML, epigenetics

Hernando Lopez-Bertoni, Johns Hopkins Medicine Department of Neurology and Neurosurgery, Baltimore, Maryland, United States of America
Epigenetics, miRNA, molecular therapeutics, GBM, Cancer stem cells, Cell reprogramming

Katherine Loree Cook, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America
Breast cancer, obesity, diet, microbiome, therapeutic resistance, and metabolism

Jin-Jian Lu, University of Macau, Taipa, Macao
Non-small cell lung cancer, cancer immunotherapy, overcoming cancer resistance and metastasis

Jun Lu, Capital Medical University Youan Hospital, Beijing, China
Hepatology and hepatocellular carcinoma, Cancer Biotherapy

Nicolò Matteo Luca Battisti, Royal Marsden NHS Foundation Trust, London, United Kingdom
Breast Cancer, Lung Cancer, Geriatric Oncology

Giovanni Luca Ceresoli, Cliniche Gavazzeni SpA, Bergamo, Italy
Mesothelioma (main), lung cancer, renal cancer, prostate cancer

Kim M. Smits, Maastricht University Medical Centre+, Maastricht, Netherlands
Renal cancer, colorectal cancer, cancer biomarkers, DNA methylation, research methodology, molecular pathological epidemiology

Anhui Madariaga, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada
Ovarian cancer, endometrial cancer, cervical cancer, vulvar cancer, vaginal cancer, drug development

Daruka Mahadevan, The University of Texas Health Science Center at San Antonio May Cancer Center, San Antonio, Texas, United States of America
Early phase therapeutics, pancreatic cancer, gastrointestinal stromal tumors, myelodysplastic syndromes and non-Hodgkin’s lymphoma, including chronic lymphocytic leukemia

Saima Shakil Malik, University of Gujrat Department of Zoology, Gujrat, Pakistan
Genomics, Proteomics, Post translational modifications, Epigenetics, DNA repair mechanisms, Drugs associated cytotoxicity, Gene–environment interaction, Oncology, Pathology and Epidemiology

Antunik Mangla, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America
Soft-tissue Sarcoma, Melanoma, Bone Sarcoma

Hitesh Mangukiya, Uppsala University, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala, Sweden
Tumor microenvironment, Tumor target discovery, Molecular signaling, Cancer metastasis, Antibody discovery, Cancer therapy

Antonino Maniaci, University of Catania Department of Surgical and Medical Sciences Advanced Technologies G. F. Ingrassia, Catania, Italy
Head and Neck cancer, oral cancer, laryngeal cancer
Consolato C. Maria Sergi, Children’s Hospital of Eastern Ontario (CHEO), Lab. Med & Pathology, University of Ottawa, Ottawa, Canada and University of Alberta, Edmonton, Alberta, Canada
Pediatric Pathology, Cardiac Pathology, Hepatology, Bone and Soft Tissue Tumors

Brigitte Marian, Medical University of Vienna Institute of Cancer Research, Vienna, Austria
Colorectal cancer, Signal transduction, Apoptosis

Luca Marinelli, University of Rome La Sapienza, Roma, Italy
Radiation oncology

Tomer M. Mark, University of Colorado Denver - Anschutz Medical Campus, Aurora, Colorado, United States of America
Multiple Myeloma, Light chain amyloidosis, Plasma cell disorders, Autologous stem cell transplantation

Paula Alexandra Martins De Oliveira, University of Tras-os-Montes and Alto Douro, Vila Real, Portugal
Pharmacology, experimental pathology and animal models for studying human diseases

Ashiq Masood, Rush University Medical Center, Chicago, Illinois, United States of America
Gastrointestinal Oncology, Cancer Genomics, Bioinformatics, precision oncology and clinical trials

Manasi Mayekar, University of California San Francisco, San Francisco, California, United States of America
DNA sequencing, genomics and proteomics, molecular and cell biology

Marco Mazzotta, Regina Elena National Cancer Institute, Roma, Italy
cancer biomarkers, Immunotherapy, Targeted therapies, Lung cancer, Breast cancer, Translational oncology

Ramsay McFarlane, North West Cancer Research, Liverpool, United Kingdom
Cancer testis antigens / germ line genes in cancer; genome stability in cancer; RNA interference and associated pathways in cancer; retrotransposons in cancer; centromeres and heterochromatin in cancer; chromatin

Veerle Melotte, Maastricht University Medical Centre+, Maastricht, Netherlands
Colorectal cancer, enteric neuroscience

Qingshu Meng, Northwestern University, Evanston, Illinois, United States of America
Cancer epigenomics, Three-dimensional genome architecture, Histone modification, IncRNA, RNA modification, Prostate cancer

Edoardo Migliori, Columbia University Irving Medical Center, New York, New York, United States of America
Cancer immunology, CAR-T, cell therapy, viral carcinogenesis, and breast cancer

Maria de Miguel, Hospital Universitario HM Sanchinarro, Madrid, Spain
Early Phase Clinical Trials

John Minna, UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, Dallas, Texas, United States of America
Breast Cancer, Genome wide mRNA, protein, and DNA analysis, Lung Cancer, Molecular biomarkers of response to cancer therapy, Molecular pathogenesis of human cancer

Mir Mohd Faheem, Council of Scientific & Industrial Research Indian Institute of Integrative Medicine, Srinagar, India
Cancer cell signaling, EMT and metastasis, cancer drug discovery

Mojtaba Mollaei, Tarbiat Modares University Department of Immunology, Tehran, Iran
Cancer, Chemotherapy, Immunotherapy, Intracellular signaling, Apoptosis, Chemoresistance, The role of MicroRNAs and Long non-coding RNAs in cancer development

Masoud Mozafari, University of Toronto, Toronto, Ontario, Canada
Nanomedicine; Biomaterials; Advanced delivery systems; Translational medicine; Tissue engineering

Pavlos Msaouel, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, Houston, Texas, United States of America
Renal cell carcinoma, Renal medullary carcinoma, SMARC1 loss, Non-clear cell renal cell carcinoma

Jibran Sualeh Muhammad, University of Sharjah, Sharjah, United Arab Emirates
Cancer Biology and Epigenetics

Nupur Mukherjee, National Institute for Research in Reproductive Health Department of Innate Immunity, Mumbai, India
Cancer Immunology, Molecular biology of Breast cancer, Translational Oncology, molecular therapeutics of cancer, Immunotherapy, transcription profiles of oncogenes, TSGs and pattern recognition receptors in cancer

Layth Mula-Hussain, University of Ottawa Divisions of Radiation Oncology, Ottawa, Ontario, Canada
Radiation oncology

Prem N. Gupta, Council of Scientific & Industrial Research Indian Institute of Integrative Medicine, Srinagar, India
Drug delivery, Cancer nanomedicine, Cancer drug targeting, Novel drug delivery system, Formulation development, Bioavailability enhancement

Geeta S. Narayanan, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, India
Radiation oncology, Comparison of HPV genotype and response to chemo radiation in cervical cancer, Evaluation of telomerase as a tumor marker in head and neck cancer, Functional MRI imaging in cervical cancer brachytherapy, MRI adapted brachytherapy in cervical cancer, Evaluating the role of Neo adjuvant chemo therapy in various cancer sites

**Amin Nassar**, Brigham and Women's Hospital, Boston, Massachusetts, United States of America

Genomics and Epigenomics of cancer

**Arash Navran**, Antoni van Leeuwenhoek Netherlands Cancer Institute, Amsterdam, Netherlands

Head and neck cancer, radiotherapy, chemoradiation, combined treatment, HNSCC, treatment toxicity, outcome, margin reduction, VMAT

**Yogendra Nayak**, Manipal College of Pharmaceutical Sciences, Manipal, India

Drug Discovery and Development, Phytomolecules, Targeted Drug Delivery, In silico Pharmacology, Preclinical testing

**K. Nayernia**, International Center for Personalized Medicine (ICPM P7MEDICINE), Düsseldorf, Germany

Persobalized Oncology Genomics

**Ntokozo Ndlovu**, University of Zimbabwe, Harare, Zimbabwe

Radiation/Clinical Oncology, Cancer, Cervical Cancer, Breast Cancer, HIV related Cancers, Prostate Cancer, Cancer Epidemiology

**Hovav Nechushtan**, Hadassah Medical Center, Jerusalem, Israel

Signal Transduction, Lung Cancer, Personalized Medicine (Oncology)

**Hema Negi**, Shanghai Jiao Tong University, Shanghai, China

Clinical Oncology, Animal tumor models , molecular oncology

**William G. Nelson**, Johns Hopkins University, Baltimore, Maryland, United States of America

Inflammation and prostatic carcinogenesis, DNA methylation and epigenetic gene silencing, Cellular responses to DNA damage, Cellular defenses against carcinogens, Drug development, Prostate cancer, Urologic cancers

**Iluliana I. Nenu**, Iuliu Hașdeianu University of Medicine and Pharmacy, Cluj-Napoca, Romania

Gastrointestinal cancers, cancer cell biology, cancer immunology

**Erika A. Newman**, C S Mott Children's Hospital, Department of Pediatric Surgery, Ann Arbor, Michigan, United States of America

Neuroblastoma and pediatric tumor biology, DNA repair, cancer xenograft models

**Taiga Nishihiro**, Moffitt Cancer Center, Tampa, Florida, United States of America

Hematopoietic cell transplantation, cellular immunotherapy, CAR T cells, myeloma, lymphoma, leukemia

**Gengming Niu**, Fifth People's Hospital of Shanghai Fudan University, Shanghai, China

Gastrointestinal cancers

**Zeribe C. Nwosu**, University of Michigan, Ann Arbor, Michigan, United States of America

Cancer Biology, Metabolism, Genomics, Novel Target Discovery

**Shyam Nyati**, University of Michigan, Ann Arbor, Michigan, United States of America

Cancer biology, signal transduction, Assay development, molecular imaging, molecular biology, biochemistry

**İnan Olmez**, Ohio State University, Columbus, Ohio, United States of America

Neuro-Oncology, brain metastasis, primary brain tumor, GBM

**Fortunato Orazio**, Foundation IRCCS National Cancer Institute, Milan, Italy

microRNA, lung cancer and extracellular vesicles

**Sandra Ortiz-Cuaran**, Cancer Research Centre Lyon, Lyon, France

Drug resistance, Drug tolerance, Liquid Biopsies, ctDNA, Lung cancer, Head and Neck Cancer

**Rodrigo Otavio de Castro Araujo**, National Institute for Cancer, Rio de Janeiro, Rio de Janeiro, Brazil

Surgical Oncology, Rectal Cancer, Translational research

**Christine O’Connor**, Cleveland Clinic, Cleveland, Ohio, United States of America

Microbiology, viral oncology, oncolytic viruses, viral infections during cancer

**Martin P. Barr**, Saint James's Hospital, Dublin, Ireland

Non-small cell lung cancer (NSCLC), VEGF signaling, microRNAs, biomarkers, drug repurposing, liquid biopsy, treatment resistance, cancer stem cell biology, translational cancer research

**Mariana P. Monteiro**, University of Porto, Porto, Portugal

Obesity Related Cancer, Gastro-intestinal Neuroendocrine Tumors

**Jérôme Paggetti**, Luxembourg Institute of Health, Strassen, Luxembourg

Chronic Lymphocytic Leukemia CLL, tumor microenvironment, exosomes, extracellular vesicles, anti-tumor immunity, hematological malignancies

**Nallasivam Palanisamy**, Henry Ford Health System, Department of Urology, Detroit, United States of America

Cancer Genomics, Molecular Pathology, Prostate Cancer, Molecular Cytogenetics, Tumor heterogeneity

**Laura Paleari**, ALIsa Regional Health System of Liguria, Genova, Italy

Cancer prevention, molecular biology, drug repurposing, health technology assessment, pharmacoeconomics
Parijat Pandey, Baba Mastnath University, Bohar, India
Nanotechnology, Oncology and Formulation Development

Janani Panneerselvam, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America
Immuono-Oncology, Tumor immunosuppressive microenvironment, Cancer therapeutics, Exosomes and Cancer prevention and drug development

George Papaxoinis, Saint Savvas Anticancer Hospital, Athens, Greece
Gastrointestinal, pancreatobiliary and neuroendocrine tumors

Bjoern Papke, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States of America
RAS oncogenes and RAS-driven cancers such as PDAC, LUAD, CRC; GTPases; Signaling networks; Drug resistance; Single-cell biology; Advanced light microscopy; Organoid models

Haeseong Park, Washington University in St Louis, Saint Louis, Missouri, United States of America
GI cancer, gastrosophageal cancer, early phase clinical trials

Eileen Parkes, University of Oxford, Oxford, United Kingdom
Cancer immunology, STING DNA repair

Sunil Pasricha, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
Oncopathology

Harvey I. Pass, NYU LANGONE MEDICAL CENTER, New York, New York, United States of America
Thoracic oncology

Sam Payabvash, Yale University, New Haven, Connecticut, United States of America
Brain tumors, Head and Neck tumors, Imaging, Artificial Intelligence, Machine learning

Guangyong Peng, Saint Louis University School of Medicine, Saint Louis, Missouri, United States of America
Immune metabolism; cell aging; TLR signaling; tumor vaccine; T cell subsets in the tumor microenvironment

Yong Peng, Sichuan University West China Hospital, Chengdu, China
Epigenetics, circular RNA, long noncoding RNA, miRNA

Sofia S. Pereira, University of Porto, Porto, Portugal
Adrenocortical tumors, obesity, endocrine tumors

Roberto Carmagnani Pestana, Albert Einstein Israelite Hospital, São Paulo, São Paulo, Brazil
Sarcoma, Gastrointestinal malignancies

Godefridus J. (Frits) Peters, VU University Medical Centre Amsterdam, Amsterdam, Netherlands
Drug resistance, conventional chemotherapy (anti-folates, anti-metabolites, platinum analogs, topoisomerase inhibitors), drug transports, drug metabolism, drug development, Prof. ABC pumps, anti-signalling drugs, gastro-intestinal tumors, pharmacogenetics, pharmacokinetics, pharmacodynamics

Iacopo Petrini, University of Pisa Department of Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy
Thoracic oncology and genomic sequencing

Philip A. Philip, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States of America
Allan Pickens, Emory University, Atlanta, Georgia, United States of America
Fas/APO-1 (CD95) and calmodulin, Fast-tracking pulmonary resections, Racial disparities in surgical management of thoracic malignancy, Patient report surgical outcomes, Thoracic oncology, Minimally invasive thoracic surgery, Lung transplantation

Kenneth Pienta, University of Michigan, Ann Arbor, Michigan, United States of America
Jason R. Pitarresi, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
Pancreatic cancer, tumor microenvironment, mouse modeling, metastasis, cellular plasticity, epithelial-to-mesenchymal transition (EMT)

Yotsawat Pomyen, Chulabhorn Royal Academy, Bangkok, Thailand
Bioinformatics, Primary Liver Cancer

Noam Falbel Pondé, ACCamargo Cancer Center, SAO PAULO, Brazil
Breast cancer, Geriatric oncology

Philippe Pourquier, Montpellier Cancer Research Institute, Montpellier, France
Molecular Pharmacology, Drug resistance, DNA topoisomerases, Prostate cancer, Colon cancer

Dinesh Pradhan, Aurora Diagnostics, Palm Beach Gardens, Florida, United States of America
Melanoma, Cancer genetics and epigenetics, Vulvar cancer, Cutaneous lymphoma

Guillem Pratx, Stanford University, Stanford, California, United States of America
Radiation therapy technology; Cancer imaging, mainly nuclear medicine, PET, radiopharmaceuticals; Cancer nanotechnology; In vitro microfluidics assays; Mathematical oncology

Vít Procházka, Palacky University Olomouc Faculty of Medicine and Dentistry, , Czechia
Lymphoma, biomarkers, imaging (PET), prognosis

Kanyi Pu, Nanyang Technological University, Singapore, Singapore
Molecular Imaging, Nanomedicine, Biomaterials, Biophotonics, Cancer phototherapy, immunotherapy
Pascal Puchois, Trans-Hit Biomarkers Inc, Montréal, Quebec, Canada
Biomarkers, central laboratory activities, diagnostics, drug development, biospecimen and biobanks,

Rafael Pulido, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain
Cancer Signal Transduction, Kinases, Phosphatases, Tumor Suppressors, MAP kinase pathways, PTEN

Juan Qian, Affiliated Hospital of Nantong University, Nantong, China
Hematology

Janaí R. Carr-Ascher, UC Davis Comprehensive Cancer Center, Sacramento, California, United States of America
Cancer Immunotherapy, Immunometabolism, Cardi-o Oncology

Giovanni Raffa, University of Messina Department of Neurosurgery, Messina, Italy
Neuro-Oncology, Brain Tumors, Gliomas, Meningiomas, Brain metastases

Shaila Rahman, EQRx Inc, Cambridge, Massachusetts, United States of America
Gene regulation and epigenetics in cancer, inflammation

Krishnaraj Rajalingam, Johannes Gutenberg University Medical Centre, Mainz, Germany
Molecular cell biology

Dayanidhi Raman, University of Toledo - Health Science Campus, Toledo, Ohio, United States of America
Breast cancer; Chemokine receptors CXCR4, CXCR2 and CCR7; Metastasis; Chemoresistance; LASP1; Breast cancer stemness and stem-like cells; Cancer Cell Motility; eIF4A

Praneela Rameshwar, Rutgers New Jersey Medical School, Newark, New Jersey, United States of America
Stem Cell, breast cancer, hematopoiesis, glioblastoma, cancer dormancy

Giridharan Ramsingh, University of Southern California, Los Angeles, California, United States of America
Acute Leukemias, Drug Resistance, Leukemia Stem Cells, Industry

Asishutosh Rao, Center for Drug Evaluation and Research, Beltsville, Maryland, United States of America
Drug discovery, drug development, biotechnology, biomarkers, mitochondrial dysfunction, autophagy, oxidative stress, protein oxidation

Muneeb U Rehman, King Saud University, Riyadh, Saudi Arabia
Cancer Biology, Toxicology, Pharmacogenomics

Ofer Reizes, Cleveland Clinic, Cleveland, Ohio, United States of America
Breast cancer, ovarian cancer, cancer stem cells, obesity, single cell sequencing, microbiome

Jun Ren, Harvard Medical School, Massachusetts General Hospital, Boston, United States of America
Tumor microenvironment, Cancer immunotherapy, CAR T therapy, Vascular biology

Janusz von Renesse, Dresden University Hospital, Dresden, Germany
Tumor Infiltrating Lymphocytes (particularly in GI Tumors), Gamma Delta T cells, and the pathophysiology of Nonalcoholic Steatohepatitis

Luisella L. Righi, University of Turin Library System, Turin, Italy
Microscopy, breast cancer, melanoma, metastasis, TGF-b signaling, dormancy

Alessandro Rizzo, University of Bologna, Bologna, Italy
Biliary tract cancer, cholangiocarcinoma, liver cancer, gastric cancer, renal cell carcinoma, urothelial carcinoma, prostate cancer, uterine leiomyosarcoma

Manglio Rizzo, Austral University Cancer Immunobiology Laboratory, Buenos Aires, Argentina
Lung cancer, immunotherapy, real world data, tumor microenvironment, extracellular matrix, hyaluronic acid, clinical trial

Benjamin Roche, Centre for Ecological and Evolutionary Research on Cancer, Montpellier, France
Ecology and evolution of cancer, transmissible cancer, mathematical modeling

Bruno Miguel Rodrigues das Neves, University of Aveiro, Aveiro, Portugal
Immunotherapy, Dendritic cell immunobiology, Dendritic cell-based immunotherapies, Tumor immunogenicity, Immunogenicity enhancers

Paulo C. Rodriguez, H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, Tampa, Florida, United States of America
Tumor Immunology, Metabolism, Immunotherapy

Ze’ev Ronai, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, United States of America
Cancer biology, signal transduction, UPR, ubiquitin proteasome system

Graziana Ronzino, Hospital Vito Fazzi, Lecce, Italy
Gynecologic oncology, Head and neck cancer, Familial cancer syndromes, Familial breast/ovarian cancer

Audrey Rousseau, University Hospital Centre Angers, Angers, France
Domaine d’expertise, Neuropathologie, tumeurs cérébrales, gliomes diffus, biologie moléculaire

Giandomenico Roviello, University of Florence, Firenze, Italy
Prostate Cancer, EGFR, Immunology, MSI, Gastric Cancer

Dhruvajyoti Roy, Helio Health, Irvine, California, United States of America
Cancer diagnostics, Cancer Genomics, Cancer Therapy, Clinical trials, Epigenetics, Liquid Biopsy, Circulating Tumor Cells (CTCs), Cell free nucleic acids, Exosomes, DNA methylation, Next Generation Sequencing (NGS), Translational cancer research, Bio-analytical chemistry, Early detection technology for cancer, Health Care and surveillance for Liver, Lung, Breast and Colorectal cancer, Nanobiotechnology for molecular detection

**Alberto Ruano Raviña**, University of Santiago de Compostela, Santiago de Compostela, Spain
Lung cancer epidemiology, Environmental risk factors, Systematic reviews and meta-analysis, Cancer Epidemiology

**Laura Russo**, University of Milan–Bicocca, Milan, Italy
Bioorganic chemistry, glycoscience, biomaterials for tissue engineering and 3d Bioprinting

**Piotr Rutkowski**, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Warszawa, Poland
Melanoma, GIST, soft tissue and bone sarcoma, cutaneous malignancies

**Marcela S. Villaverde**, University of Buenos Aires, Buenos Aires, Argentina
Lipofection, Gene Therapy, Tumors, Cell Survival, Cancer, Transfection, Cell Culture, Molecular Cell Biology, Flow Cytometry, Metabolism

**Anwar Saeed**, The University of Kansas Cancer Center Drug Discovery, Delivery and Experimental Therapeutics, Kansas City, Kansas, United States of America
Immunotherapy and Immune modulation in Gastrointestinal malignancies, Gastric and Esophageal Cancer, Colorectal cancer and Hepatocellular carcinoma

**Nasreena Sajjad**, University of Kashmir, Srinagar, India
Antioxidants, Antioxidant Activity, Reactive Oxygen Species, Phytochemicals, Natural Product Chemistry, Extraction, Chromatography, Bioactivity, Biomarkers, Food Chemistry

**Ikuko Sakamoto**, Yamanashi Prefecture Central Hospital, Kofu, Japan
Gynecologic oncology, endometrial cancer, ovarian cancer, cervical cancer

**Gloria Sanchez**, University of Antioquia, Medellin, Colombia
Human Papillomavirus tests and vaccines, Molecular biomarkers in cervical carcinogenesis, Cervical cancer prevention in low resource settings, Risk factors and risk models for personalized breast cancer prevention

**Celeste Sánchez-Romero**, University of the Republic Uruguay, Montevideo, Uruguay
Oral and maxillofacial pathology, molecular pathology, head and neck cancers

**Alberto Sandri**, San Luigi Gonzaga University Hospital, Thoracic Surgery Unit, Orbassano, Italy
Thoracic oncology, minimally invasive surgery (uniportal VATS), technology applied to thoracic surgery, lung cancer, lung lobectomy, lung segmentectomy, NSCLC, lung function test, mesothelioma, neuroendocrine tumours of the lung and thymus

**Francesca Sanguedolce**, Foggia University Hospital, Foggia, Italy
Pathology, prostate cancer, bladder cancer, testis cancer, immunohistochemistry, predictive markers

**Julien Sarkis**, Saint Joseph University, Beirut, Lebanon
Urology (Genito-urinary tumors- prostate cancer, Bladder cancer, Kidney cancer, Cancer biomarkers, Immunotherapy)

**Yasushi Sasaki**, Sapporo Medical University, Sapporo, Japan
Molecular mechanisms of human carcinogenesis, Functional analysis of p53 family, Cancer genetics (Ovarian cancer, Gastrointestinal cancer, Pancreatic cancer)

**Klaus Schreiber**, CDx Diagnostics Inc, Suffern, New York, United States of America
Cytomorphology of precancerous conditions

**Morgan S Schrock**, OHIO STATE UNIVERSITY, Columbus, Ohio, United States of America
DNA damage, chromosomal fragile sites, chromosome congression, veterinary oncology, canine models of cancer, antimitotic therapies

**Alka Sehgal**, Government Medical College and Hospital, Chandigarh, India
Obstetrics and Gynecology

**Satyaki Sengupta**, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
Transcriptional regulation in cancer, cancer epigenetics, regulation of anti-tumor immune response, MYC/MYCN-driven cancers, pediatric neuroblastoma, RB-E2F tumor suppressor pathway

**Nilay Shah**, Nationwide Children’s Hospital, Columbus, Ohio, United States of America
Pediatric Oncology, Neuroblastoma, Sarcomas, Long noncoding RNAs, Signal transduction, Transcription Factors, Oncogenesis, Clinical Trials

**Vinit Shanbhag**, University of Missouri, Columbia, Missouri, United States of America
Biochemistry, Biology of cancer, Drug discovery, and development, Molecular biology and signaling

**Hongchang Shen**, Shandong University, Jinan, China
Biochemistry, Genetics and Molecular Biology, cancer immunology and microbiology

**Zhiyong Shen**, Southern Medical University Nanfang Hospital, , China
The molecular mechanism of occurrence and development of colorectal cancer, Cancer metabolism, Transcriptional regulation, immune microenvironment) Minimally invasive treatment for gastrointestinal diseases, especially laparoscopic surgery for colorectal cancers.

Yaqin Shi, First Affiliated Hospital of Soochow University, Suzhou, China
Targeted therapy and combination therapy of triple negative breast cancer

Anthony Shields, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States of America
Gastrointestinal Oncology

Rachna Shroff, ARIZONA CANCER CENTER, Tucson, Arizona, United States of America
GI cancers, pancreatic cancer, biliary cancers, cholangiocarcinoma, gallbladder cancer, biomarkers, translational research, immunotherapy

Surendra Kumar Shukla, UNIVERSITY OF NEBRASKA MEDICAL CENTER, Omaha, Nebraska, United States of America
Pancreatic Cancer, Liver Cancer, Cancer Metabolism, Therapy Resistance, Cachexia

Cornelis F.M. Sier, Leiden University Medical Center, Leiden, Netherlands
cancer, invasion, angiogenesis, metastasis, markers, tracers, imaging

Rajesh Sinha, The University of Alabama, Tuscaloosa, Alabama, United States of America
Molecular Biology, Cancer Biomarker, Infectious diseases, Drug development

Charalampos Siotos, Rush University Medical Center, Chicago, Illinois, United States of America
Breast cancer, mastectomy, breast reconstruction, oncoplastic surgery

Karel Smetana, Jr., Charles University First Faculty of Medicine, , Czechia
Tumour microenvironment

Maria Soledad Sosa, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America
Dormancy, cancer metastasis, dissemination, residual disease

Rosalinda Sorrentino, University of Salerno Department of Pharmacy, Fisciano, Italy
Immuono- oncology, immunotherapy

Aris Spathis, General University Hospital Attikon, Athens, Greece
Molecular and cellular techniques with expertise in flow cytometry for diagnosis, typing, monitoring and treatment of malignancies

Stefania Staibano, University of Naples Federico II Department of Advanced Biomedical Sciences, Napoli, Italy
Histopathology, immunohistochemistry, digital pathology, cancer, melanoma, Head and Neck cancer, prognosis, predictive tissue biomarkers

Sabrina Strano, Regina Elena National Cancer Institute, Roma, Italy
Identification of new biomarkers in oncology, Drug repurposing for targeting the Hippo signalling pathway

Izabela Sumara, Institut of Genetics and Molecular and Cellular Biology, Ilkirch Graffenstaden, France
Cell division and ubiquitin

Suchitra Sundaram, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States of America
Lymphoma, CLL, Lymphoid Malignancies, Multiple myeloma

Argiris Symeonidis, University of Patras, Patras, Greece
Gaucher disease, hematology, myelodysplastic syndromes, multiple myeloma, chronic myeloproliferative neoplasms, anemia, erythropoiesis, lymphoproliferative disorders, targeted treatments in hematology

Tomasz Szczepanski, Medical University of Silesia, Katowice, Poland
Pediatric Oncology, Pediatric Hematology, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Minimal Residual Disease, Flow Cytometry, Immunoglobulin Gene, Leukemia, Oncology

Andrzej T Siomiński, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America
Skin cancer, keratinocytes, melanoma, melanocytes, melanin pigmentation, vitamin D in general, melatonin in general, photocarcinogenesis and photobiology

Takayuki Takahama, Kindai University Hospital, , Japan
Translational research about genomic testing, biomarker research for targeted therapy, and the study about systemic chemotherapy's resistant mechanisms.

Moshe Talpaz, University of Michigan, Ann Arbor, Michigan, United States of America
Hematologic malignancies and phase one drug development, leukemia, immunotherapy

Yuichi Tambo, Kanazawa University Hospital, Kanazawa, Japan
Lung Cancer, NSCLC, SCLC, Immuno Oncology, Targeted Therapy, Translational Research, Clinical Trial

Hui Tang, Peking Union Medical College Hospital, Beijing, China
Macromolecular science

Jinshan Tang, Michigan Technological University, Houghton, Michigan, United States of America
AI, Medical Image Analysis, Radiology, Computer Aided Cancer detection

Yongguang Tao, China Central South University, Changsha, China
Cancer epigenetics

Randall K Ten Haken, University of Michigan, Ann Arbor, Michigan, United States of America

AUTHOR INFORMATION PACK 12 Jun 2021 www.elsevier.com/locate/tranon
Radiation oncology

Elizabeth Thomas, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
Oncogenic signaling, tumor progression & metastasis and cancer therapeutics

Pramod K Tiwari, Jiwaji University, Gwalior, India
Cancer genetics and epigenetics, biomarkers

Kenneth To, The Chinese University of Hong Kong, Shatin, Hong Kong
Multidrug resistance, Cancer epigenetics, Drug repurposing

Nham Tran, University of Technology Sydney, Sydney, Australia
Head and Neck cancers, miRNA gene regulation, miRNA diagnostics, HPV16 cancers and virology, salivary biomarkers for cancer detection

Giuseppe Troiano, University of Foggia, Foggia, Italy
Evidence-based Medicine, Meta-analysis, Prognostic Biomarker, oral squamous cell carcinoma

William KF Tse, National University Corporation Kyushu University, Fukuoka, Japan
Cell migration, Deubiquitinase, Disease model, Omics, Zebrafish

Siddhartha Tyagi, Baylor College of Medicine Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Houston, Texas, United States of America
Breast cancer, MYC, Splicing, Preclinical trials, Xenografts, Development of GEMM and PDX models, Molecular biology, Development and design new vectors, CRISPER, Development of in vivo screen technologies, Q PCR,

Ilya Ulasov, I M Sechenov First Moscow State Medical University Institute of Regenerative Medicine, Moskva, Russian Federation
Gene therapy, neuro-oncology, glioblastoma, brain metastases, cell death, autophagy

Paola Ulivi, Ministry of Health, Milan, Italy
Cancer Biology, Molecular Oncology, Lung Cancer, Colorectal Cancer, Metastasis, Cancer Biomarkers, Tumor Markers, Cancer Diagnostics

Maruti Chandra Uppalapati, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Protein engineering, Antibody engineering, Phage display

Alfonso Urbonucci, Oslo University Hospital, Institute for Cancer Research, Oslo, Norway
Prostate Cancer, Chromatin Biology, Androgen receptor, gene regulation, gene expression

Hery Urrea, Biomedical Neuroscience Institute, Santiago, Chile
Brain cancer, Melanoma, ER stress, Unfolded protein Response, Inversion, Cell migration, Metastasis

Filippo Veglia, Moffitt Cancer Center, Tampa, Florida, United States of America
Immunology, metabolism, myeloid cells, neuro-oncology

Monica Venere, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States of America
Glioblastoma, Cancer stem cells, DNA damage response, Cell cycle

Louis Vermeulen, VU University Medical Centre Amsterdam, Amsterdam, Netherlands
Molecular oncology, translational oncology, stem cells, cancer heterogeneity, colorectal cancer

Jeewan Ram Vishnoi, All India Institute of Medical Sciences, New Delhi, India
Surgical Oncology, Gastrointestinal Cancer, Head, and Neck Cancer, Breast Cancer, Cancer Epidemiology, Cancer Biomarkers, Translational Oncology

Siniša Volarević, University of Rijeka, Rijeka, Croatia
Ribosome biogenesis and cancer, cell growth, p53

Mariza Vorster, University of Pretoria, Pretoria, South Africa
Nuclear medicine, theranostic, Ga-68-based PET, PET/CT, molecular imaging, targeted radionuclide therapy

Konstantinos Voskarides, University of Cyprus, Lefkosia, Cyprus
Evolutionary theory and cancer, Cancer Genetics, Cancer epidemiology

Joe W. Ramos, University of Hawaii Cancer Center, Honolulu, Hawaii, United States of America
Roger Wahba, University Hospital Cologne, Köln, Germany
Oncologic Surgery, Liver Surgery, Peritoneal Carcinomatosis, circulating Tumor DNA in HCC, CCC and secondary liver malignancies

Ethan Walker, Case Western Reserve University, Cleveland, Ohio, United States of America
Molecular imaging, Photodynamic and photoimmunotherapy of cancer, Role of Junctional Adhesion Molecules in breast and prostate cancer development, Tumor stem cells and Tumor microenvironment

Meiyun Wang, Henan Provincial People's Hospital, Zhengzhou, China
Neuroradiology, magnetic resonance imaging

Ming-Da Wang, Second Military Medical University, Shanghai, China
Metabolic reprogramming, Cancer cell proliferation and invasion, Oncogene and signaling pathway, Tumor development and progression, Glycolysis, Fatty acid oxidation and synthesis

Yuexiang Wang, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China
Cancer genetics, Tumor suppressor, Gastrointestinal stromal tumor, Pancreatic cancer

Saman Warnakulasuriya, King's College London, London, United Kingdom
Oral Cancer, Screening, Risk factors, Epidemiology

**David J. Waxman**, Boston University, Boston, Massachusetts, United States of America
P450 metabolism of anticancer drugs, Metronomic chemotherapy, Immunogenic chemotherapy

**Ralph Weischebaum**, University of Chicago, Chicago, Illinois, United States of America
Radiation and cellular oncology

**C. Benedikt Westphalen**, University Hospital Munich Department of Internal Medicine III - Oncology, München, Germany
Gastrointestinal Oncology (pancreatic / biliary), Precision Oncology

**Christopher Willett**, Duke University School of Medicine, Durham, North Carolina, United States of America
Radiation oncology

**Terence Williams**, OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER, Columbus, Ohio, United States of America
Radiation oncology, thoracic and gastrointestinal cancers

**C. Benedikt Westphalen**, Charite University Hospital Berlin Campus Benjamin Franklin, Berlin, Germany
Radiation and cellular oncology

**Burghardt Wittig**, Molecular Biology & Integral Biomathics, Berlin, Germany
Cellular regulatory processes originating from chromatin topology and structure. Innate immunity in cancer immunotherapy and infection,

**Lee H Wong**, Monash University, Clayton, Victoria, Australia
Chromatin, histone variants, telomeres, centromeres, ATRX, Epigenetics

**Che-Wei Wu**, Kaohsiung Medical University College of Medicine, , Taiwan
Head and Neck Cancer, Thyroid Cancer, Oral Cancer, Thyroid and Parathyroid Surgery, Intraoperative Neural Monitoring

**Jing Wu**, National Cancer Institute, Bethesda, Maryland, United States of America
Neuro-Oncology

**Junhua Wu**, Jiangsu Key Laboratory for Molecular Medicine, Nanjing, China
Application of polymer materials in energy storage direction, polymer electrolyte for lithium ion battery, gel electrolyte, surface coatings,

**Li Xie**, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Biostatistics, Epidemiology, Clinical trials, Cancer

**Peng Xie**, Shandong Cancer Hospital and Institute, Jinan, China
Gynecologic Oncology, Radiation Oncology

**Shang Xie**, Peking University School of Stomatology, Beijing, China
Dentistry, Evidence based medicine, Head and neck cancer, Head and neck reconstruction, Head and neck surgery, Stomatology

**Jiheng Xu**, NYU Langone Health Perlmutter Cancer Center, New York, New York, United States of America
Cancer signaling transduction, Cell signaling transduction

**Fevzi Yalniz**, Legend Biotech, Piscataway, New Jersey, United States of America
Hematological malignancies including myeloid malignancies such as myelodysplastic syndromes and acute myeloid leukemias, lymphoid malignancies including chronic and acute leukemias as well as lymphomas, Adoptive cellular therapies including CAR-T, Stem cell transplantation

**Masayoshi Yamaguchi**, University of Hawai‘i Cancer Center, Honolulu, Hawaii, United States of America
Cancer bone metastasis, prostate cancer, breast cancer, cell signaling

**Jian Yang**, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Breast cancer research

**Jilong Yang**, Tianjin Medical University, Tianjin, China
Sarcoma, melanoma, surigical oncology

**Tian Yang**, Eastern Hepatobiliary Surgery Hospital, Shanghai, China
Hepatobiliary Cancer, Hepatocellular Carcinoma, Oncologic Surgery

**Yongyong Yang**, Northwestern University, Evanston, Illinois, United States of America
Prostate cancer, Molecular Biology, Long non-coding RNA (lncRNA), MicroRNA, Non-histone protein methylation modification, and Epigenetics

**Özlem Yedier Bayram**, Koc University, İstanbul, Turkey
Molecular biology of cancer, breast cancer, drug resistance

**Chien-Fu Yeh**, Taipei Veterans General Hospital, Taipei, Taiwan
Head and neck cancer, surigical oncology

**Syn Yeo**, University of Cincinnati, Cincinnati, Ohio, United States of America
Breast Cancer Stem Cells, Autophagy

**Jun (Vivien) Yin**, Mayo Clinic, Department of Health Sciences Research, Jacksonville, Florida, United States of America
Bayesian adaptive clinical trial designs, predictive modeling, master protocols, precision oncology, surrogate endpoint, leukemia, hepatobiliary cancer

**Byunghee B. Yoo**, Harvard Medical School, Boston, Massachusetts, United States of America
Bayesian adaptive clinical trial designs, predictive modeling, master protocols, precision oncology, surrogate endpoint, leukemia, hepatobiliary cancer
RNA interference for the regulation of post-transcriptional target genes by use of microRNAs and siRNAs, the inhibition of cancer metastasis and the prevention of multi-drug resistance in chemotherapy, the optimization of nanotemplates to equip siRNA, miRNA, targeting peptides, fluorescent dyes and/or radioisotope ligands

Wang Yu, National Cancer Centre Singapore, Singapore, Singapore
biomarkers, recurrence, personalized treatment

Hongwei Zhang, The Affiliated Hospital of Southwest Medical University, Luzhou, China
Blood Platelets and Neoplasms

Lianjun Zhang, Chinese Academy of Medical Sciences Suzhou Institute of Systems Medicine, Suzhou, China
Tumor immunology and immunotherapy, tumor microenvironment, cancer metabolism and immunometabolism

Lu Zhang, Clemson University, Clemson, South Carolina, United States of America
Cancer epidemiology, lung cancer screening, personalized breast cancer treatment, prostate cancer treatment

Meng Zhang, Anhui Medical University, Institute of Urology, Anhui, China
Prostate cancer, bioinformatics, immunotherapy

Weijie Zhang, Baylor College of Medicine Lester and Sue Smith Breast Center, Houston, Texas, United States of America
Breast Cancer Oncogenesis, Cancer Metastasis

Zhao Zhang, The University of Texas Health Science Center at Houston, Houston, Texas, United States of America
Bioinformatics, Cancer genomics, non-coding RNA, gene regulation

Zijian Zhang, Baylor College of Medicine, Houston, Texas, United States of America
Cancer Epigenetics and Drug Discovery

Sunyi Zheng, University Medical Center Groningen, Department of Radiation Oncology, Groningen, Netherlands
medical imaging processing, deep learning, pulmonary nodules, lung cancer, computer-aided detection, prognosis

Dachen Zhou, The Second Hospital of Anhui Medical University, Anhui, China
Hepatocarcinoma, mRNA translation, Liver cirrhosis, Cancer treatment

Hengbo Zhou, MASSACHUTSES GENERAL HOSPITAL, Boston, Massachusetts, United States of America
Tumor immunology, EMT and metastasis

Hongcheng Zhu, Fudan University Shanghai Cancer Center, Shanghai, China
Radiation Oncology

Daniel Zweifel, Cantonal Hospital Winterthur, Winterthur, Switzerland
Various publications on varying topics, mainly reconstructive surgery and virtual planning of such reconstruction
GUIDE FOR AUTHORS

Your Paper Your Way
We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.
To find out more, please visit the Preparation section below.

Scope and Mission
Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.

Peer Review
This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More information on types of peer review.

The Editors are committed to a rapid review process with high quality standards. Every effort will be made to obtain reviews and return editorial decisions to the authors within 3 weeks of manuscript receipt. When manuscripts are accepted contingent on revision, the revised work must be received within three weeks of the decision date, unless prior arrangements are made with the Editors.

Guidelines for Editorial Decisions
The primary criteria for judging which manuscripts are published are originality and scientific/clinical significance. Manuscripts may be editorially declined on these grounds, even if the experimental work appears technically sound.

Prior Publication
The submitted material must not be published nor submitted elsewhere, except in abstract form.

Types of Articles
Translational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and perspectives, and letters to the editor.

Original Research Article
Original, full-length research articles which have not been published previously, except in a preliminary form, may be submitted. Original Studies present results of original basic and translational research.

Mechanics: Original research articles should include a structured abstract and should be divided into sections (Introduction, Materials and Methods, Results and Discussion). Original research articles have a limit of 4,500 words and no more than 50 references. Authors are asked to limit the number of figures and/or tables to 6.

Reviews and Opinions
Review Article

Review articles offer a balanced account of newly emerging or rapidly progressing fields and provide a guide to the most relevant recent literature and prospects for future research.

They should briefly set the background and then concentrate on setting recent findings in context. It is crucial that they should give a balanced view of developments, even in fields that are controversial, and authors must never concentrate unduly on their own research. Although Reviews do allow room for some speculation and debate, it should be made clear where the authors' own opinions are being presented.
References selected for publication should be chosen for their importance, ease of access, and for the "further reading" opportunities they provide; citations to papers published in non-peer-reviewed supplements are discouraged.

**Mechanics:** Reviews articles should contain a short abstract stating the goal of the review, an introduction, discussion, and conclusion. Reviews have a limit of 4,500 words and no more than 80 references. Authors are asked to limit the number of figures and/or tables to 6. Reviews should have no more than 5 authors without prior agreement of the editors.

**Opinion article**

Opinions may reflect an individual perception, involvement, or contribution to oncology, and should be prepared in a similar way to a Review. Opinions should present a personal and original perspective on an important research-related topic of interest to the cancer research community, rather than a balanced review of this topic.

The aim should be to stimulate debate or new research, cover controversial topics, or provide a new framework for, or interpretation of, an old problem or current issue, or speculate on the implications of some recent research. Although Opinion articles can be more 'forward looking' than Reviews, please avoid being overly speculative. Please note that articles that outline recent advances in a field rather than give a strong opinion on them are not suitable for this section of the journal; neither are hypotheses without any published support.

**Mechanics:** Opinion articles have a limit of 2,500 words and no more than 60 references. Authors are asked to limit the number of figures and/or tables to 6. Opinions should have no more than 3 authors without prior approval from the editors. Opinions should include an abstract.

**Short Communications**

**Spotlights**

Spotlights are short articles intended to provide a quick update on one or two recent research articles published in other journals that signify a major advancement in a specific field of Cancer. Spotlights should give additional insight on the topic, highlighting broader implications for the field that have not already been provided by the original paper(s). Although subjective, Spotlight articles should not be used to dwell excessively on the author's own research, to introduce new (unpublished) data, or to excessively criticize the work of others, except where criticism is constructive.

Please send a pre-submission inquiry to the Journal Inbox: transonc@elsevier.com

**Mechanics:** Spotlights have a limit of 1,500 words and no more than 10 references. Authors are asked to limit the number of figures and/or tables to 2. Spotlights should include an abstract.

**Commentaries**

Commentaries are short articles that highlight one or several research papers published in a recent issue of the Journal, placing the results in context for the journal's broad readership. Commentaries are commissioned by the editors to accompany new papers in *Translational Oncology*. Unsolicited contributions are not considered.

**Mechanics:** Commentaries have a limit of 1,500 words and no more than 10 references. Authors are asked to limit the number of figures and/or tables to 2. Commentaries should include an abstract.

**Perspectives**

Perspectives are short pieces that aim to highlight for a very broad audience a significant recent development in the field or to raise awareness about a topic of general interest. Possible topics can include future outlook essays that serve to introduce or encourage research in a new field, reflections and new insights on long-standing questions and debates, and general analyses of common scientific practices or tools used in a field.
Perspectives should not include unpublished data, simulations, or meta-analyses. Although subjective, a perspective should not be used to dwell excessively on the author's own research or to excessively criticize the research of others, except where criticism is constructive. The introduction of hypothesis and models is encouraged, and the articles should be written with a very personal perspective, but it is important to mention other viewpoints where they exist to place the work discussed in a context for the nonspecialist reader.

Please send a pre-submission inquiry to the Journal Inbox: transonc@elsevier.com

Mechanics: Perspectives have a limit of 1,200 words and no more than 10 references. Authors are asked to limit the number of figures and/or tables to 2. Perspectives should have no more than 3 authors without prior approval from the editors. Perspectives should include an abstract.

Letters to the Editors
Letters to the Editors which comment directly on work that has previously been published in the Journal will be considered. The author of the paper on which the Letter is commenting will be contacted and invited to respond.

Mechanics: Letters have a limit of 1,000 words and no more than 10 references. Authors are asked to limit the number of figures and/or tables to 1. Letters should not include an abstract or have more than 3 authors without prior approval from the editors.

Editorials
Editorials serve as the voice of Translational Oncology and are written by the Journal's Editors and Guest Editors.

BEFORE YOU BEGIN

Ethics in publishing
Please see our information on Ethics in publishing.

Studies in humans and animals
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

Informed consent and patient details
Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.
Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double anonymized) or the manuscript file (if single anonymized). If there are no interests to declare then please state this: 'Declarations of interest: none'. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.

Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

Preprints
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

Author contributions
For transparency, we encourage authors to submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Authorship statements should be formatted with the names of authors first and CRediT role(s) following. More details and an example

Authorship
When submitting a paper authors must complete the Authorship form, download from here. This form confirms that all authors agree to publication if the paper is accepted and allows authors to declare any conflicts of interest, sources of funding and ethical approval (if required). Please download the form and submit it with your paper. Submissions that do not include a completed form will be returned without review.

Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

**Article transfer service**
This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. [More information.]

**Copyright**
Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (see [more information](#) on this). Permitted third party reuse of open access articles is determined by the author’s choice of [user license](#).

**Author rights**
As an author you (or your employer or institution) have certain rights to reuse your work. [More information.]

**Sequence Data**
GenBank/EMBL/DDBJ database accession numbers are required for all new sequences before they can be published in *Translational Oncology*. Sequence data should be sent to GenBank before the manuscript is submitted for review. If the number is not available at the time of submission, it can be added at the page-proof stage.

*Elsevier supports responsible sharing*
Find out how you can share your research published in Elsevier journals.

**Role of the funding source**
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

**Open access**
Please visit our [Open Access page](#) for more information.

**Language (usage and editing services)**
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier’s WebShop. Please note the journal also offers complimentary language editing at the discretion of the editor.

**Submission**
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor’s decision and requests for revision, is sent by e-mail.

*Submit your article*

**PREPARATION**

**NEW SUBMISSIONS**
Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.
As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

References
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

Formatting requirements
There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.
If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.
Divide the article into clearly defined sections.

Figures and tables embedded in text
Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should be placed directly below the figure or table.

REVISED SUBMISSIONS
Use of word processing software
Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). See also the section on Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure
Subdivision - unnumbered sections
Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.

Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Results
Results should be clear and concise.

Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.
**Essential title page information**

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript letter immediately after the author’s name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

**Twitter handle**

If you would like your Twitter handle to be included on your published paper, please provide it on your title page.

**Highlights**

Highlights are mandatory for this journal as they help increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: example Highlights.

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

**Abstract**

A concise and factual abstract is required not exceeding 250 words. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

**Keywords**

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

**Abbreviations**

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

**Acknowledgements**

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

**Formatting of funding sources**

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].
It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

Artwork
Electronic artwork
General points
- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files.

A detailed guide on electronic artwork is available. You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
- EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.
- TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
- TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
- TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

Please do not:
- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

Illustration services
Elsevier's Author Services offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

Figure captions
Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.

Video
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the
same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

**Data visualization**

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

**Supplementary material**

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

**Research data**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

**Data linking**

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

**Mendeley Data**

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley Data. The datasets will be listed and directly accessible to readers next to your published article online.
Data statement
To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.

Submission Checklist
The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

Ensure that the following items are present:
Authors understand they will be responsible for paying the publication fee if the submission is accepted.

One author has been designated as the corresponding author with contact details:
- E-mail address
- Full postal address
- Phone numbers

All necessary files have been uploaded, and contain:
- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations
- Manuscript has been ‘spell-checked’ and ‘grammar-checked’
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Web)

For any further information please visit our customer support site at https://service.elsevier.com.

AFTER ACCEPTANCE

Online proof correction
To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints
The corresponding author will be notified and receive a link to the published version of the open access article on ScienceDirect. This link is in the form of an article DOI link which can be shared via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier’s Author Services.

AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com